Lucillia Bezu

TL;DR: This work discusses current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD, and suggests that novel therapeutic regimens that trigger ICD are urgently awaited.

TL;DR: It is shown that crizotinib is an effective stimulator of immunogenic cell death and can potentiate the efficacy of immune checkpoint blockade and can exert their anticancer effect through indirect immune-dependent mechanism.

TL;DR: Machine-learning approaches were used to determine the physicochemical properties of drugs that induce ICD, revealing that the sole ER stress response relevant to the algorithm is eIF2α phosphorylation with its downstream consequences CALR exposure, stress granule formation and autophagy induction.

TL;DR: Preclinical and clinical progress in the use of peptide-based vaccines as anticancer therapeutics is reviewed, with particular focus on personalized peptide vaccination.

TL;DR: It is shown that eIF2α phosphorylation is a quintessential hallmark of ICD that can be detected by immunohistochemistry in tumor samples and hence is a classic hallmark of anticancer chemotherapeutics.